After giving piperacillin‑tazobactam and clindamycin, the patient developed severe chills, rigors, and hypotension without rash; could this be a bacteriolysis reaction rather than an allergic reaction, and should the antibiotics be continued?

Immediate Management: Stop Piperacillin-Tazobactam Now

This reaction is most consistent with a hypersensitivity reaction to piperacillin-tazobactam, and the drug should be discontinued immediately. The FDA label explicitly warns that "serious and occasionally fatal hypersensitivity (anaphylactic/anaphylactoid) reactions (including shock) have been reported in patients receiving therapy with piperacillin and tazobactam" and mandates discontinuation if an allergic reaction occurs 1.

Why This is Likely Hypersensitivity, Not Bacteriolysis

The clinical presentation of severe chills, rigors, and hypotension without rash occurring shortly after antibiotic administration strongly suggests an immediate hypersensitivity reaction rather than bacteriolysis (Jarisch-Herxheimer reaction). Key distinguishing features:

• Timing: Hypersensitivity reactions to piperacillin-tazobactam can occur rapidly after infusion
• Hypotension with rigors: This constellation is characteristic of anaphylactoid reactions, which can present without cutaneous manifestations in up to 20% of cases
• Bacteriolysis reactions: Typically occur 1-2 hours after the first dose of antibiotics for spirochetal infections (syphilis, Lyme disease) or specific bacterial infections, not commonly with the organisms treated by piperacillin-tazobactam

The absence of rash does not exclude hypersensitivity—the FDA label specifically notes that anaphylactic/anaphylactoid reactions including shock can occur, and these systemic reactions may present without cutaneous findings 1.

Immediate Actions Required

1. Discontinue piperacillin-tazobactam immediately (FDA mandate) 1
2. Treat the hypotensive episode: Fluids, vasopressors if needed, antihistamines, corticosteroids as clinically indicated
3. Do NOT rechallenge with piperacillin-tazobactam
4. Switch to alternative antibiotic: Choose based on the infection source and local resistance patterns—avoid other beta-lactams initially given potential cross-reactivity

Regarding Clindamycin

Clindamycin is unlikely to be the culprit given:

• Different drug class (lincosamide vs. beta-lactam)
• Hypersensitivity reactions to clindamycin typically manifest as rash or, rarely, Stevens-Johnson syndrome, not acute hypotension with rigors
• However, monitor closely if continuing clindamycin

You can cautiously continue clindamycin while switching the piperacillin-tazobactam to an alternative agent, but maintain vigilance for any worsening symptoms.

Critical Documentation

Document this reaction as a piperacillin-tazobactam hypersensitivity reaction in the medical record and allergy list. This patient should:

• Avoid all formulations of piperacillin-tazobactam
• Exercise caution with other beta-lactams until formal allergy evaluation
• Consider allergy/immunology referral for future skin testing if beta-lactam antibiotics are essential 2

Common Pitfall to Avoid

Do not assume this is "just a reaction to rapid infusion" or bacteriolysis and continue the drug. The FDA is explicit: if a hypersensitivity reaction occurs, discontinue the drug 1. The combination of hypotension and systemic symptoms represents a potentially life-threatening reaction that can worsen with continued exposure.